EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions

Julius Bogomolovas, Ju Chen

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci179958 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Julius Bogomolovas und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Muscle, Skeletal, Benzylamines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility. This therapeutic mechanism has proven effective for patients with HCM independent of having a primary gene mutation in myosin. In this issue of the JCI, Buvoli et al. report that muscle hypercontractility is a mechanism of pathogenesis underlying muscle dysfunction in Laing distal myopathy, a disorder characterized by mutations altering the rod domain of β myosin heavy chain. The authors performed detailed physiological, molecular, and biomechanical analyses and demonstrated that myosin ATPase inhibition can correct a large extent of muscle abnormalities. The findings offer a therapeutic avenue for Laing distal myopathy and potentially other myopathies. This Commentary underscores the importance of reevaluating myosin activity's role across myopathies in general for the potential development of targeted myosin inhibitors to treat skeletal muscle disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle, SkeletalBenzylaminesHumansCardiomyopathy, HypertrophicMyosin Heavy ChainsDistal MyopathiesAnimalsMutationMyosinsUracil

Substanzen

Myosin Heavy ChainsMYK-461MyosinsBenzylaminesUracil

Zitieren

APA

Bogomolovas, J., & Chen, J. (2024). A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions. Journal of Clinical Investigation. https://doi.org/10.1172/jci179958

Vancouver

Bogomolovas J, Chen J. A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions. Journal of Clinical Investigation. 2024. doi:10.1172/jci179958

BibTeX
@article{Bogomolovas2024,
  author = {Bogomolovas, Julius and Chen, Ju},
  title = {A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci179958}
}
Kostenlos starten →